Mirikizumab Demonstrates Superiority over Placebo in Phase 3 Maintenance Study in Ulcerative Colitis, Supporting Regulatory Submissions in 2022

Significantly more patients treated with mirikizumab maintenance dosing achieved the primary endpoint of clinical remission at one year (52 weeks), and all key secondary endpoints were met Mirikizumab is the first and only anti-IL23p19 to demonstrate maintenance of clinical remission in a Phase 3